文献速递真菌感染

粉碎泊沙康唑缓释片用于儿童抗真菌预防和治疗

Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本研究回顾性审计了18个月内墨尔本皇家儿童医院≤18岁患者经肠内喂养管给予粉碎泊沙康唑缓释片的情况,共12例患儿,预防8例、治疗4例,所有患儿均达到目标浓度,预防中位剂量7 mg/kg/日、治疗13 mg/kg/日,1例发生喂养管堵塞。

要点

  • 粉碎泊沙康唑缓释片经肠内喂养管给药可使儿童达到目标血药浓度。
  • 预防中位剂量7 mg/kg/日,治疗中位剂量13 mg/kg/日。
  • 1例患儿发生喂养管堵塞,归因于泊沙康唑,未观察到其他不良反应。

核心结论

  • 粉碎泊沙康唑缓释片经肠内喂养管给药可作为儿童抗真菌预防和治疗中达到治疗性泊沙康唑浓度的一种方法。

研究设计与样本

  • 回顾性审计,纳入墨尔本皇家儿童医院≤18岁、经肠内喂养管接受粉碎泊沙康唑缓释片且至少有一次稳态谷浓度测定的患者,为期18个月。

主要发现

  • 共12例患儿,中位年龄9岁(范围2至14岁),预防8例、治疗4例。
  • 所有患儿均达到目标浓度;预防中位剂量7 mg/kg/日(范围5至11),治疗中位剂量13 mg/kg/日(范围9至20)。
  • 达到治疗水平的中位时间:预防7天(范围5至14),治疗20天(范围15至35)。
  • 1例患儿发生肠内喂养管堵塞,归因于泊沙康唑;未观察到其他不良反应。

关键数值与推荐

  • 泊沙康唑目标浓度:预防≥0.7 mg/L,治疗侵袭性真菌感染≥1.0 mg/L。

临床怎么用

  • 作者认为,粉碎泊沙康唑缓释片经肠内喂养管给药可用于儿童抗真菌预防和治疗以达到治疗性泊沙康唑浓度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Therapeutic drug monitoring (TDM) is recommended for posaconazole to achieve target concentrations of ≥0.7 mg/L and ≥1.0 mg/L for prophylaxis and treatment of invasive fungal infection (IFI), respectively. However, target attainment is challenging with the oral suspension, particularly in children. Here, we describe our experience using crushed delayed-release tablet (DRT) in a paediatric cohort, with a focus on TDM. METHODS: We undertook a retrospective audit of crushed posaconazole DRT administration via enteral feeding tubes (EFTs) for patients aged ≤18 years over 18 months at The Royal Children's Hospital Melbourne who had at least one trough concentration measured at steady state. Details of patient demographics, posaconazole dosing, monitoring and adverse effects were recorded. RESULTS: Twelve patients with a median age of 9 years (range 2 to 14) received posaconazole DRT via EFT for prophylaxis (n = 8) or treatment (n = 4). All children achieved target concentration, with a median dose of 7 mg/kg/day (range 5 to 11) for prophylaxis and 13 mg/kg/day (range 9 to 20) for treatment. The median time to reach therapeutic levels was 7 days (range 5 to 14) for prophylaxis and 20 days (range 15 to 35) for treatment. One child had blockage of their EFT, which was attributed to posaconazole. No other adverse effects were observed. CONCLUSIONS: Crushed posaconazole DRT administered via EFT may be used as a method of attaining therapeutic posaconazole concentrations in children for antifungal prophylaxis and treatment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Weerdenburg H, Gwee A, Haeusler GM, et al. Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children. J Antimicrob Chemother. 2024. PMID: 39475156. doi:10.1093/jac/dkae373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。